The genomic complexity of primary human prostate cancer.

TitleThe genomic complexity of primary human prostate cancer.
Publication TypeJournal Article
Year of Publication2011
AuthorsBerger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L, Fennell T, Parkin M, Saksena G, Voet D, Ramos AH, Pugh TJ, Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J, Simons JW, Kitabayashi N, MacDonald TY, Kantoff PW, Chin L, Gabriel SB, Gerstein MB, Golub TR, Meyerson M, Tewari A, Lander ES, Getz G, Rubin MA, Garraway LA
Date Published2011 Feb 10
KeywordsCarrier Proteins, Case-Control Studies, Cell Adhesion Molecules, Chromatin, Chromosome Aberrations, Chromosome Breakpoints, Epigenesis, Genetic, Gene Expression Regulation, Neoplastic, Genome, Human, Humans, Male, Prostatic Neoplasms, PTEN Phosphohydrolase, Recombination, Genetic, Signal Transduction, Transcription, Genetic

Prostate cancer is the second most common cause of male cancer deaths in the United States. However, the full range of prostate cancer genomic alterations is incompletely characterized. Here we present the complete sequence of seven primary human prostate cancers and their paired normal counterparts. Several tumours contained complex chains of balanced (that is, 'copy-neutral') rearrangements that occurred within or adjacent to known cancer genes. Rearrangement breakpoints were enriched near open chromatin, androgen receptor and ERG DNA binding sites in the setting of the ETS gene fusion TMPRSS2-ERG, but inversely correlated with these regions in tumours lacking ETS fusions. This observation suggests a link between chromatin or transcriptional regulation and the genesis of genomic aberrations. Three tumours contained rearrangements that disrupted CADM2, and four harboured events disrupting either PTEN (unbalanced events), a prostate tumour suppressor, or MAGI2 (balanced events), a PTEN interacting protein not previously implicated in prostate tumorigenesis. Thus, genomic rearrangements may arise from transcriptional or chromatin aberrancies and engage prostate tumorigenic mechanisms.

Alternate JournalNature
PubMed ID21307934
PubMed Central IDPMC3075885
Grant List2 P50 CA090381-11 / CA / NCI NIH HHS / United States
DP2 OD002750 / OD / NIH HHS / United States
DP2 OD002750-01 / OD / NIH HHS / United States
R33 CA126674 / CA / NCI NIH HHS / United States
R33 CA126674-03 / CA / NCI NIH HHS / United States
/ / Howard Hughes Medical Institute / United States